Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Clinically confirmed multiple sclerosis \[MS\];~* Expanded Disability Status Scale \[EDSS\] score less or equal to 6;~* Two documented relapses in the previous 3 years, and one clinical relapse during the preceding year;~* Screening magnetic resonance imaging \[MRI\] scan fulfilling the criteria for a diagnosis of MS.~Exclusion Criteria:~* Clinically relevant cardiovascular, hepatic, hematologic, neurological, endocrine or other major systemic disease;~* Pregnant or nursing woman;~* Wish to parent children during the trial or following the trial (men and women were required to practice effective contraception during the trial and for 24 months after drug discontinuation);~* Prior treatment with interferon \[IFN\], gamma-globulin, glatiramer acetate, or other noncorticosteroid immunomodulatory therapies in the 4 months prior to the trial;~* Use of cladribine, mitoxantrone, or other immunosuppressant agents such as azathioprine, cyclophosphamide, cyclosporin, methotrexate or mycophenolate before enrollment;~* Any known condition or circumstance that would prevent in the investigator's opinion compliance or completion of the study.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (for teriflunomide),~* two tablets once daily for 1 week then,~* one tablet once daily for 35 weeks.
- Teriflunomide 7 mg (Type: EXPERIMENTAL): Teriflunomide 7 mg:~* two tablets once daily for 1 week then,~* one tablet once daily for 35 weeks.
- Teriflunomide 14 mg (Type: EXPERIMENTAL): Teriflunomide 14 mg:~* two tablets once daily for 1 week then,~* one tablet once daily for 35 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).